CRISPR/Cas9 Technology

CRISPR/Cas9 genome editing system becomes a powerful tool to target and modify genomic sequence, allowing a previously unattainable level of efficacy, specificity and efficiency. This system uses non-coding RNAs to guide the Cas9 nuclease to generate sequence-specific DNA cleavage of target loci across the genome. WuXi Biology has fully implemented this technology platform to offer CRISPR/Cas9 based gene knock-in or knock-out to support gene function studies and target validation efforts.

CRISPR, Cas9, genomic DNA, KI, KO
  • CRISPR/Cas9 Applications:
    • Specific gene knock-out
    • Precise genome editing, such as site-mutation knock-in or add reporter gene tag
    • Rapid generation of genetically engineered mice
    • Genome-wide scale knock-out for screening
  • Key Advantages of CRISPR/Cas9:
    • Simple and fast two-component system with high efficiency and low cost
    • Permanently turn off genes at the DNA level; clean background
    • Offers access to non-coding regions of the genome

CRISPR/Cas9 Gene Editing Services

  • sgRNA design, plasmid construction, and validation
  • Knock-out of single or multiple target sequences
  • Site-mutation knock-in and gene tag knock-in
  • Isogenic cell line generation with gene knock-out/knock-in
  • Genome-wide CRISPR/Cas9 library screen

CRISPR in vivo services for model generation and rare genetic disease

  • From genome editing to disease models and PK-PD-efficacy studies
  • Well-established in vivo gene editing platform in rodent
  • 100+ KO and KI mouse/rat lines generated
  • Generation of genetically engineered animal models (GEAM) for drug discovery for rare genetic disease
    • Knockout and knock in services in mouse and rat
    • Humanization: in situ replace mouse gene with matched human exons or introns
    • Transgenic, genotyping, and phenotyping
    • In vitro fertilization
    • Embryo and sperm cryopreservation
    • Drug administration, animal and tissue manipulation and histopathology
    • AAALAC accreditation and GLP compliance